- Dehydroevodiamine
-
- $0.00 / 20mg
-
2023-02-24
- CAS:67909-49-3
- Min. Order: 20mg
- Purity: ≥98%(HPLC)
- Supply Ability: 10 g
- Dehydroevodiamine
-
- $1.00 / 1KG
-
2020-01-05
- CAS: 67909-49-3
- Min. Order: 1KG
- Purity: 95-99%
- Supply Ability: 1ton
|
| | Dehydroevodiamine Basic information |
| Product Name: | Dehydroevodiamine | | Synonyms: | Dehydroevodiamine;14-Methyl-5(7H)-oxo-8,13-dihydroindolo[2',3':3,4]pyrido[2,1-b]quinazoline-14-ium;5,7,8,13-Tetrahydro-14-methyl-5-oxoindolo[2',3':3,4]pyrido[2,1-b]quinazolin-14-ium;8,13-Dihydro-14-methyl-5-oxoindolo[2',3':3,4]pyrido[2,1-b]quinazolinium inner salt;14-Methyl-5-oxo-7,8-dihydro-5H-indolo[2',3':3,4]-pyrido[2,1-b]quinazolin-14-ium-13-ide;Indolo[2',3':3,4]pyrido[2,1-b]quinazolinium,8,13-dihydro-14-methyl-5-oxo-, inner salt;dehydrovodiamine | | CAS: | 67909-49-3 | | MF: | C19H15N3O | | MW: | 301.35 | | EINECS: | 200-258-5 | | Product Categories: | reagent;standard substance | | Mol File: | 67909-49-3.mol |  |
| | Dehydroevodiamine Chemical Properties |
| Melting point | 190-192℃ | | storage temp. | 2-8°C | | solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | | form | powder | | color | Yellow |
| | Dehydroevodiamine Usage And Synthesis |
| Chemical Properties | White crystalline powder, soluble in methanol, ethanol, DMSO and other organic solvents, derived from dried near-ripe fruit of Evodia sclerosus. | | Uses | Dehydroevodiamine is a novel alkaloid which displays butyrylcholinesterase inhibitory activity in vivo. | | Biological Activity | Dehydroevodiamine, a quinazoline alkaloid isolated from Evodiae Fructus, has antiarrhythmic effects on guinea pig ventricular myocytes. It inhibits LPS-induced expression of iNOS, COX-2, PGE2 and NF-κB in mouse macrophages. | | Physiological effects | Dehydroevodiamine has an antihypertensive and antitumor effects. | | in vitro | Dehydroevodiamine (0-50 μM; 2 hours) inhibits iNOS and COX-2 expression and prevents degradation of IκB-α in LPS induced RAW 264.7 macrophages. Dehydroevodiamine (0-50 μM; 2 hours) inhibits a LPS -induced increase in the iNOS and COX-2 mRNA expression. Western Blot Analysis | Cell Line: td> | RAW 264.7 macrophage cells | | Concentration: | 10 μM, 30 μM, 50 μM | | Incubation Time: | pretreated 2 hours | | Result: | Reduced iNOS and COX-2 expression and increased IκB-α expression. | RT-PCR < td class="col1"> Cell Line: | RAW 264.7 macrophage cells | | Concentration: | 10 μM, 30 μM, 50 μM | td> | Incubation Time: | pretreated 2 hours | | Result: | Reduced iNOS and COX-2 mRNA expression. | | | target | | Target | Value | NF-κB
() | COX-2
() | iNOS
() | PGE2
() |
|
| | Dehydroevodiamine Preparation Products And Raw materials |
|